Gout - news, views, blogs - Biotech, Pharma and Life Science Channel
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40.
So, we know that it's a form of arthritis, but there's a lot more to it. Gout is a painful form of arthritis that is caused by high uric acid levels in your blood (hyperuricemia). Gout attacks occur when excess uric acid forms crystals, causing inflammation in your joints that leads to swelling and pain. As your uric acid level rises, so does the potential for gout and gout flares. Over time, gout attacks can become more severe, last longer, and occur more often. Decreasing your uric acid to the recommended level (less than 6 mg/dL) can reduce the risk of gout attacks over the long term.
Source: Gout.com
Twitter Account - @GoutBio - 
News Articles
PITTSBURGH, May 22, 2013 /PRNewswire/ -- The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly t...
Jim Belushi, Savient And CreakyJoints Team Up To Shift The Conversation About Gout
BRIDGEWATER, N.J., May 22, 2013 /PRNewswire/ -- Jim Belushi, Savient Pharmaceuticals and patient advocacy group CreakyJoints have released a new online video to encourage candid discussion about...
Weight loss may reduce gout flares by suppressing inflammatory response
Obese patients with gout may benefit from undergoing bariatric surgery, as the resulting weight loss could help to reduce the frequency of their gout flares, new research suggests.Previous research ha...
Renal Ventures Management Announces New President and CEO of its Infusion Subsidiary
Greg Meadows appointed to manage and lead expansion of RV Infusion Partners, LLC Renal Ventures Management, LLC, a leading provider of dialysis services for pati...
Vitamin C supplements 'do not lower uric acid levels in people with gout'
Vitamin C supplementation does not have a clinically significant effect on uric acid (urate) levels in people with gout, a study has found.Researchers at the University of Otago in New Zealand assesse...
Report reveals poor physical activity adherence among people with arthritis
The majority of people with arthritis do not do enough walking, according to a study in the US.Published by the Centres for Disease Control and Prevention (CDC), the report looks at the prevalence of...
BioCryst to Present at Two Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the...
People with gout and elevated uric acid face increased risk of death
A study has highlighted the combined impact of gout and elevated uric acid levels on patients' risk of premature death.Researchers at the University of Limerick analysed data on more than 15,700 p...
BioCryst to Announce First Quarter 2013 Financial Results May 7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013. BioCryst will host a co...
Gout - a step closer to the elusive 'cure'
Gout, the most common form of inflammatory arthritis, is supposedly easy to treat. But a new study shows that misconceptions of this painful condition are preventing effective treatment. Jane Tadman...
Events
None
Companies
Mountain View Pharmaceuticals, Inc.
MVP is a privately-held California corporation with expertise in the application of advanced polymer-coupling technology to make protein-based drugs safer and longer acting. To da...
CD Diagnostics (www.cddiagnostics.com) is developing a series of immunoassays to detect the cause of joint pain using joint fluid analysis. The assays use a small sample of a pati...
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory disea...
EnzymeRx, LLC is a private, clinical stage biotechnology company developing enzyme-based therapeutics. Our lead product pegsitacase is in phase 1 clinical studies and being develo...
Clinical Trials
Characterizing and Diagnosis’s of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients
The condition Charcot foot has been known in more than 130 years, and yet there still remains a large effort to find the cause, diagnostic and medical treatment of the condition. Charcot...
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat compared to allopurinol in reducing serum urate levels in subjects with gout.
Validation Study of Physical Measurement of Tophi
The purpose of this study is to determine the inter- and intra-rater reproducibility of direct physical measurement of tophus nodules in subjects with gout.
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
The purpose of this study is to determine the efficacy of febuxostat in reducing serum urate levels in subjects with gout.
Long-Term Safety of Febuxostat in Subjects With Gout.
The purpose of this study is to evaluate the long-term safety of febuxostat in maintaining serum urate levels within clinically acceptable levels in subjects with gout.
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
A Study comparing febuxostat, allopurinol and placebo in subjects with gout.
A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout
A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
The purpose of this study is to determine whether PEG-uricase (a chemically modified recombinant mammalian enzyme that degrades uric acid) is effective in controlling hyperuricemia in pati...
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
The purpose of this study is to evaluate the safety and efficacy of febuxostat versus allopurinol in subjects with gout.
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects m...
PubMed Articles
Gout is an inflammatory joint disorder characterized by hyperuricaemia and precipitation of monosodium urate crystals in the joints. In the present study, we aimed to investigate the anti-inflammatory...
Beyond gout: uric acid and cardiovascular diseases.
Abstract Objectives: This article discusses the results of clinical and experimental studies that examine the association of hyperuricemia and gout with cardiovascular (CV) disease. Methods: Key paper...
Therapy: Efficacy of rilonacept in preventing gout flare during ULT.
Synthetic drugs such as allopurinol and benzbromarone are commonly used to treat the complex pathogenesis of gout, a metabolic disease that results from an inflammation of the joints caused by precipi...
OBJECTIVE: To provide a quantitative map of relationships between metabolic traits, genome-wide association (GWAS) variants, metabolic syndrome (MetS), and metabolic diseases through factor analysis a...
Interleukin-1-mediated diseases.
Interleukin-1 (IL-1)-mediated diseases are caused by an inappropriately high production and release of IL-1 beta which results in a multitude of symptoms, e.g. arthritis, exanthema, conjunctivitis, se...
Crystal arthritis: Is HLAB genotyping the future of gout pharmacogenomics?
Crystal arthritis: New ACR guidelines for gout management hold some surprises.
Videos
Body Invaders: Gout
This disease was once called the "disease of the rich".
Medical and Biotech [MESH] Definitions
Hyperuricemia
Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
Sulfinpyrazone
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Tenosynovitis
Inflammation of the synovial lining of a tendon sheath. Causes include trauma, tendon stress, bacterial disease (gonorrhea, tuberculosis), rheumatic disease, and gout. Common sites are the hand, wrist, shoulder capsule, hip capsule, hamstring muscles, and Achilles tendon. The tendon sheaths become inflamed and painful, and accumulate fluid. Joint mobility is usually reduced.
Uricosuric Agents
Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
Arthritis, Gouty
Arthritis, especially of the great toe, as a result of gout. Acute gouty arthritis often is precipitated by trauma, infection, surgery, etc. The initial attacks are usually monoarticular but later attacks are often polyarticular.
